Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: A meta-analysis of randomized controlled trials

Shi,Lei‑Zhi; Heng,Rui; Liu,Shi‑Min; Leng,Fei‑Yan

doi:10.3892/etm.2015.2545

Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: A meta-analysis of randomized controlled trials

Authors:
- Lei‑Zhi Shi
- Rui Heng
- Shi‑Min Liu
- Fei‑Yan Leng
View Affiliations

Affiliations: Department of Thoracic Surgery, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China, Department of Internal Medicine, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China
Published online on: June 3, 2015 https://doi.org/10.3892/etm.2015.2545
Pages: 816-822

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to compare the health outcomes of catheter ablation therapy against those of antiarrhythmic drugs (AADs) in the management of atrial fibrillation (AF). The effects of catheter ablation and AADs on a number of parameters were compared, including AF recurrence, all‑cause mortality, stroke/transient ischemic attack (TIA) and quality of life (QoL). A systematic literature search of PubMed, Embase and the Cochrane Central Register of Controlled Trials was conducted to obtain relevant randomized controlled trials. The relative risks (RRs) and 95% confidence intervals (CIs) of AF recurrence, all‑cause mortality and stroke/TIA between catheter ablation and AADs were subsequently calculated. Weighted mean differences (WMDs) and 95% CIs were used to evaluate the QoL between the two therapy groups. In total, 11 randomized trials, which included 1,763 AF patients, were eligible for the meta‑analysis. Overall, the results indicated that catheter ablation produces superior outcomes compared with AADs in reducing AF recurrence (RR, 0.47; 95% CI, 0.38‑0.58; P<0.001) and improving the QoL (physical component summary: WMD, 2.23; 95% CI, 0.24‑4.21; P=0.03; mental component summary: WMD, 2.69; 95% CI, 0.04‑5.35; P=0.05). However, no statistically significant difference was identified between the two groups with regard to the incidence of all‑cause mortality (RR, 0.87; 95% CI, 0.37‑2.06; P=0.76) and stroke/TIA (RR, 1.83; 95% CI, 0.73‑4.55; P=0.20). In summary, catheter ablation was demonstrated to markedly reduce AF recurrence and improve QoL when compared with AAD therapy. However, the incidence rates of all‑cause mortality and stroke/TIA were comparable between catheter ablation and AAD therapy.

View Figures

View References

1	Naccarelli GV, Varker H, Lin J and Schulman KL: Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 104:1534–1539. 2009. View Article : Google Scholar : PubMed/NCBI
2	Wilke T, Groth A, Mueller S, et al: Incidence and prevalence of atrial fibrillation: An analysis based on 8.3 million patients. Europace. 15:486–493. 2013. View Article : Google Scholar : PubMed/NCBI
3	Zhou ZQ and Hu DY: An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol. 18:209–216. 2008. View Article : Google Scholar : PubMed/NCBI
4	Piccini JP, Hammill BG, Sinner MF, et al: Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993–2007. Circ Cardiovasc Qual Outcomes. 5:85–93. 2012. View Article : Google Scholar : PubMed/NCBI
5	Camm AJ, Lip GY, De Caterina R, et al: ESC Committee for Practice Guidelines (CPG): 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 33:2719–2747. 2012. View Article : Google Scholar : PubMed/NCBI
6	Wann LS, Curtis AB, January CT, et al: 2006 Writing Committee Members; ACCF/AHA Task Force Members: 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 123:104–123. 2011.PubMed/NCBI
7	Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB and Levy D: Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 98:946–952. 1998. View Article : Google Scholar : PubMed/NCBI
8	Verma A, Macle L, Cox J and Skanes ACCCS Atrial Fibrillation Guidelines Committee: Canadian Cardiovascular Society atrial fibrillation guidelines 2010: Catheter ablation for atrial fibrillation/atrial flutter. Can J Cardiol. 27:60–66. 2011. View Article : Google Scholar : PubMed/NCBI
9	Krittayaphong R, Raungrattanaamporn O, Bhuripanyo K, et al: A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. J Med Assoc Thai. 86 (Suppl 1):8–16. 2003.PubMed/NCBI
10	Wazni OM, Marrouche NF, Martin DO, et al: Radiofrequency ablation vs. antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: A randomized trial. JAMA. 293:2634–2640. 2005. View Article : Google Scholar : PubMed/NCBI
11	Oral H, Pappone C, Chugh A, et al: Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med. 354:934–941. 2006. View Article : Google Scholar : PubMed/NCBI
12	Stabile G, Bertaglia E, Senatore G, et al: Catheter ablation treatment in patients with drug-refractory atrial fibrillation: A prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J. 27:216–221. 2006. View Article : Google Scholar : PubMed/NCBI
13	Jais P, Cauchemez B, Macle L, et al: Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: Rhe A4 study. Circulation. 118:2498–2505. 2008. View Article : Google Scholar : PubMed/NCBI
14	Forleo GB, Mantica M, De Luca L, et al: Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: Results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol. 20:22–28. 2009. View Article : Google Scholar : PubMed/NCBI
15	Wilber DJ, Pappone C, Neuzil P, et al: Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial. JAMA. 303:333–340. 2010. View Article : Google Scholar : PubMed/NCBI
16	Pappone C, Vicedomini G, Augello G, et al: Radiofrequency catheter ablation and antiarrhythmic drug therapy: A prospective, randomized, 4-year follow-up trial: The APAF study. Circ Arrhythm Electrophysiol. 4:808–814. 2011. View Article : Google Scholar : PubMed/NCBI
17	Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, Sterns LD, Beresh H, Healey JS and Natale ARAAFT-2 Investigators: Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation (RAAFT 2): A randomized trial. JAMA. 311:692–700. 2014. View Article : Google Scholar : PubMed/NCBI
18	Cosedis Nielsen J, Johannessen A, Raatikainen P, et al: Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 367:1587–1595. 2012. View Article : Google Scholar : PubMed/NCBI
19	Blandino A, Toso E, Scaglione M, et al: Long-term efficacy and safety of two different rhythm control strategies in elderly patients with symptomatic persistent atrial fibrillation. J Cardiovasc Electrophysiol. 24:731–738. 2013. View Article : Google Scholar : PubMed/NCBI
20	Higgins JPT and Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. updated. March. 2011The Cochrane Collaboration. 2011, Available from. https://www.cochrane-handbook.org
21	Guyatt GH, Oxman AD, Vist GE, et al GRADE Working Group: GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 336:924–926. 2008. View Article : Google Scholar : PubMed/NCBI
22	Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA, et al: Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med. 172:997–1004. 2012. View Article : Google Scholar : PubMed/NCBI
23	Tsadok MA, Jackevicius CA, Essebag V, et al: Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation. 126:2680–2687. 2012. View Article : Google Scholar : PubMed/NCBI
24	Pappone C, Rosanio S, Augello G, et al: Mortality, morbidity and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: Outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol. 42:185–197. 2003. View Article : Google Scholar : PubMed/NCBI
25	Khaykin Y, Wang X, Natale A, et al: Cost comparison of ablation versus antiarrhythmic drugs as first-line therapy for atrial fibrillation: An economic evaluation of the RAAFT pilot study. J Cardiovasc Electrophysiol. 20:7–12. 2009. View Article : Google Scholar : PubMed/NCBI
26	McKenna C, Palmer S, Rodgers M, et al: Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom. Heart. 95:542–549. 2009. View Article : Google Scholar : PubMed/NCBI
27	Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T and Cohen DJ: Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2:362–369. 2009. View Article : Google Scholar : PubMed/NCBI
28	Noro M, Kujime S, Ito N, et al: Cost effectiveness of radiofrequency catheter ablation vs. medical treatment for atrial fibrillation in Japan. Cost performance for atrial fibrillation. Circ J. 75:1860–1866. 2011. View Article : Google Scholar : PubMed/NCBI
29	Noheria A, Kumar A, Wylie JV Jr and Josephson ME: Catheter ablation vs. antiarrhythmic drug therapy for atrial fibrillation: A systematic review. Arch Intern Med. 168:581–586. 2008. View Article : Google Scholar : PubMed/NCBI
30	Piccini JP, Lopes RD, Kong MH, Hasselblad V, Jackson K and Al-Khatib SM: Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: A meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol. 2:626–633. 2009. View Article : Google Scholar : PubMed/NCBI
31	Bonanno C, Paccanaro M, La Vecchia L, Ometto R and Fontanelli A: Efficacy and safety of catheter ablation versus antiarrhythmic drugs for atrial fibrillation: A meta-analysis of randomized trials. J Cardiovasc Med (Hagerstown). 11:408–418. 2010. View Article : Google Scholar : PubMed/NCBI